INTERNATIONAL PATENT: DEBIOPHARM INTERNATIONAL S.A. FILES APPLICATION FOR "DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR"

GENEVA, April 28 -- DEBIOPHARM INTERNATIONAL S.A. (Forum "apres-demain"Chemin Messidor 5-71006 Lausanne) filed a patent application (PCT/EP2024/079491) for "DRUG COMBINATION COMPRISING ANTI-CD37 ANTIBODY MAYTANSINE CONJUGATE AND BCL2 INHIBITOR OR PI3K INHIBITOR" on Oct 18, 2024. With publication no. WO/2025/083205, the details related to the patent application was published on Apr 24, 2025.

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Inventor(s): BERTONI, Francesco (Fondazione per l'Istituto Oncologico diRicerca, Institute of Oncology Research,Via Francesco Chiesa 56500 Bellinzona), ARRIBAS, Alberto (Fonda...